In a report released this morning, Roth Capital analyst Joseph Pantginis reinitiated coverage on BioLineRx Ltd. (BLRX) with a Buy rating and an $8.
In a research note released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (REGN) and a price target of $382.
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies Inc. (PTN) and a price target of $6.
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Stemline Therapeutics, Inc. (STML) and a price target of $62.
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharmaceutical (LGND) and a price target of $92.00 following …
In a research report published today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Ligand Pharmaceuticals, Inc. (LGND), and a price target of $92.
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Curis Inc. (CRIS), and a price target of $10.
A bearish article published Monday afternoon on Seeking Alpha claimed that LGND stock has the potential to lose 100% of its value based …
In a research note issued earlier today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Galena Biopharma, Inc. (GALE), and a …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated coverage on Can-Fite Bio Pharma (CANF) with a Buy rating and a $28.00 price target.
